TL;DR
This study identifies a new, aggressive subtype of clear cell renal cell carcinoma (ccRCC) characterized by high immune infiltration, a specific EMT signature, and the expression of Fibroblast Activation Protein (FAP) on tumor cells. This FAP-positive subtype is linked to poorer survival and increased liver metastasis, suggesting FAP as a potential therapeutic target and biomarker.
What Problem Does This Paper Address?
Clear cell renal cell carcinoma (ccRCC) is known for its high immune infiltration, which often correlates with poor outcomes. While epithelial-to-mesenchymal transition (EMT), immune suppression, and cancer-associated fibroblasts (CAFs) are linked to worse prognoses in advanced ccRCC, their specific roles and interactions in localized disease were less clear. The authors aimed to dissect the complex tumor microenvironment (TME) in highly inflamed localized ccRCC to identify specific cell subsets and states that contribute to poor prognosis, particularly focusing on the interplay between EMT and immune cells.
Methods
The researchers employed multiplexed immunofluorescence (mIF), a powerful technique that allows for the simultaneous detection of multiple protein markers within a single tissue sample. They used a comprehensive panel of 33 antibodies to profile 1,728 tissue cores from 435 localized ccRCC patients. This allowed them to spatially characterize various cell types (immune cells, endothelial cells, fibroblasts, tumor cells) and their states within different regions of the tumor (center, invasive border, and adjacent benign tissue). They also utilized hierarchical clustering to identify distinct TME subsets and performed Kaplan-Meier survival analyses and Cox regression to assess the prognostic significance of identified markers. For validating FAP antibody specificity, they used CRISPR-Cas9 knockout in a cell line.
Datasets
The study utilized a dataset of 1,728 tissue cores collected from 435 localized ccRCC patients. This cohort was divided into an independent discovery set (n=196) and a validation set (n=239) to confirm findings. The tissue microarrays (TMAs) were constructed from formalin-fixed, paraffin-embedded (FFPE) surgical specimens.
Key Insights and Ideas
- FAP as a dual marker: The study highlights that Fibroblast Activation Protein (FAP) isn't just a marker for cancer-associated fibroblasts (CAFs) but is also expressed on tumor cells themselves in an aggressive ccRCC subtype. This dual expression is a key finding.
- EMT and immune suppression go hand-in-hand: The research strongly links the loss of epithelial markers (indicating EMT) with an increase in immunosuppressive immune cells (like exhausted T cells and M2 macrophages) and FAP-expressing CAFs. This suggests a coordinated effort by the tumor to evade immune surveillance.
- Spatial context matters: The findings emphasize the importance of the tumor border, where EMT and FAP expression are particularly pronounced, suggesting this region is critical for disease progression and metastasis.
- FAP as a prognosticator: Tumor cell FAP expression emerged as a more potent predictor of metastasis risk than patient age, underscoring its clinical relevance.
Key Results
- CD45+ cell density predicts poor survival: Higher densities of CD45+ immune cells in tumor centers, borders, and even benign areas were associated with shorter recurrence-free survival (RFS).
- FAP+ tumor cells define an aggressive subtype: In CD45high tumors, a low EpiStain phenotype (indicating EMT) was associated with a higher frequency of FAP+ ccRCC cells at the tumor border. These FAP+ tumors had a significantly lower 5-year RFS rate (26%) compared to FAP-negative CD45high tumors (50%).
- FAP predicts liver metastasis: Stronger tumor cell FAP expression was significantly associated with a higher likelihood of liver metastasis, even after adjusting for clinical covariates.
- FAP+ CAFs are enriched at tumor edges: FAP+ stromal cells were significantly increased at the tumor border in CD45high, EMT+ tumors and correlated with poor RFS.
- Immunosuppressive microenvironment: Tumors with higher FAP levels and EMT phenotypes showed an enrichment of immunosuppressive immune cells, including exhausted T cells and M2-like macrophages.
- FAP as an independent predictor: Tumor cell FAP expression was validated as an independent predictor of outcome in early-stage ccRCC (pT1-2) and in patients who later developed metastases and received sunitinib.
Limitations and Future Work
The authors acknowledge the retrospective design of their study. They were unable to analyze the impact of ccRCC cancer cell states and TME characteristics on the outcomes of adjuvant immunotherapy (like pembrolizumab) because the patients had undergone surgery before its widespread use. This is a key area for future research.
The study suggests several promising future directions:
- FAP-targeted imaging (FAPI-PET): This could be explored for early detection of high-risk ccRCC to improve patient stratification and guide treatment decisions.
- FAP-targeted therapies: Radioligand therapy and bispecific antibodies targeting FAP-expressing cells could offer novel treatment strategies, potentially by overcoming resistance to existing therapies and stimulating the immune system.
- Integrating genomic profiling: Future studies should integrate observations of immune infiltration, stromal components, and cancer cell states with genomic profiling to better stratify patients for tailored treatments.
- Investigating FAP in metastatic settings: The role of FAP in liver metastasis and its potential contribution to resistance against anti-angiogenic therapies warrants further investigation.
Summary updated